Cathelicidins and functional analogues as antisepsis molecules

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 8, 2007, Pages 993-1004

  Mookherjee, Neeloffer ^a   Rehaume, Linda M ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cathelicidin; Host defence peptide; Inflammation; Pattern recognition receptor; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; BETA DEFENSIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE BAC2A; CATHELICIDIN ANTIMICROBIAL PEPTIDE BMAP 18; CATHELICIDIN ANTIMICROBIAL PEPTIDE BMAP 2; CATHELICIDIN ANTIMICROBIAL PEPTIDE BMAP 27; CATHELICIDIN ANTIMICROBIAL PEPTIDE BMAP 28; CATHELICIDIN ANTIMICROBIAL PEPTIDE BMAP 29; CATHELICIDIN ANTIMICROBIAL PEPTIDE CRAMP; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATHELICIDIN ANTIMICROBIAL PEPTIDE PMAP 23; CATHELICIDIN ANTIMICROBIAL PEPTIDE SMAP 29; CATHELICIDIN DERIVATIVE; DEFENSIN; DROTRECOGIN; IMMUNOMODULATING AGENT; INDOLICIN; PR 39; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTISEPSIS; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENDOTOXEMIA; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTISEPSIS; HUMANS; LIPOPOLYSACCHARIDES; MULTIGENE FAMILY;

EID: 34547731337     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.8.993     Document Type: Review

References (97)

1. BARON RM, BARON MJ, PERRELLA MA: Pathobiology of sepsis: are we still asking the same questions? Am. J. Respir. Cell Mol. Biol. (2006) 34(2):129-134.
2. BONE RC, BALK RA, CERRA FB et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest (1992) 101(6):1644-1655.
3. NGUYEN HB, RIVERS EP, ABRAHAMIAN FM et al.: Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann. Emerg. Med. (2006) 48(1):28-54.
4. LEVY MM, FINK MP, MARSHALL JC et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. (2003) 29(4):530-538.
5. BALK RA: Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations. Dis. Man. (2004) 50(4): 168-213.
6. ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. (2001) 29(7):1303-1310.
7. SHARMA S, KUMAR A: Septic shock, multiple organ failure, and acute respiratory distress syndrome. Curr. Opin. Pulm. Med. (2003) 9(3): 199-209.
8. MOOKHERJEE N, BROWN KL, BOWDISH DM et al.: Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. (2006) 176(4):2455-2464.
9. RANGEL-FRAUSTO MS: Sepsis: still going strong. Arch. Med. Res. (2005) 36(6):672-681.
10. ANNANE D, BELLISSANT E, CAVAILLON JM: Septic shock. Lancet (2005) 365(9453):63-78.
11. CREAGH EM, O'NEILL LA: TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. (2006) 27(8):352-357.
12. BEUTLER B, POLTORAK A: Sepsis and evolution of the innate immune response. Crit. Care Med. (2001) 29(7 Suppl.):S2-S6; discussion S6-S7.
13. CRISTOFARO P, OPAL SM: The Toll-like receptors and their role in septic shock. Expert Opin. Ther. Targets (2003) 7(5):603-612.
14. BROWN KL, COSSEAU C, GARDY JL, HANCOCK REW: Complexities of targeting innate immunity to treat infection. Trends Immunol. (2007) 28(6):260-266.
15. PHILPOTT DJ, GIRARDIN SE: The role of Toll-like receptors and Nod proteins in bacterial infection. Mol. Immunol. (2004) 41(11):1099-1108.
16. AKIRA S: TLR signaling. Curr. Top. Microbiol. Immunol. (2006) 311:1-16.
17. GAN L, LI L: Regulations and roles of the interleukin-I receptor associated kinases (IRAKs) in innate and adaptive immunity. Immunol. Res. (2006) 35(3):295-302.
18. KOBAYASHI K, HERNANDEZ LD, GALAN JE et al.: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 110(2):191-202.
19. JANSSENS S, BURNS K, VERCAMMEN E, TSCHOPP J, BEYAERT R: MyD88S, a splice variant of MyD88, differentially modulates NF-κB- and AP-1-dependent gene expression. FEBS Lett. (2003) 548(1-3):103-107.
20. DIDIERLAURENT A, BRISSONI B, VELIN D et al.: Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell Biol. (2006) 26(3):735-742.
21. HOTCHKISS RS, KARL IE: The pathophysiology and treatment of sepsis. N. Engl J. Med. (2003) 348(2):138-150.
22. CAVAILLON JM, ADIB-CONQUY M, FITTING C, ADRIE C, PAYEN D: Cytokine cascade in sepsis. Scand. J. Infect. Dis. (2003) 35(9):535-544.
23. ADIB-CONQUY M, ADRIE C, FITTING C et al.: Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit. Care Med. (2006) 34(9):2377-2385.
24. SINGER M, DE SANTIS V, VITALE D, JEFFCOATE W: Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet (2004) 364(9433):545-548.
25. MARSHALL JC, VINCENT JL, FINK MP et al.: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada (25 - 26 October 2000). Crit. Care Med. (2003) 31(5):1560-1567.
26. OPAL SM, CROSS AS: Clinical trials for severe sepsis. Past failures, and future hopes. Infect. Dis. Clin. North Am. (1999) 13(2):285-297, vii.
27. HANCOCK REW, DIAMOND G: The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. (2000) 8(9):402-410.
28. YANG D, BIRAGYN A, KWAK LW, OPPENHEIM JJ: Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. (2002) 23(6):291-296.
29. BOWDISH DME, DAVIDSON DJ, HANCOCK REW: A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Prot. Pept. Sci. (2005) 6:35-51.
30. SHINNAR AE, BUTLER KL, PARK HJ: Cathelicidin family of antimicrobial peptides: proteolytic processing and protease resistance. Bioorg. Chem. (2003) 31(6):425-436.
31. XIAO Y, CAI Y, BOMMINENI YR et al.: Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity. J. Biol. Chem. (2006) 281(5):2858-2867.
32. BASANEZ G, SHINNAR AE, ZIMMERBERG J: Interaction of hagfish cathelicidin antimicrobial peptides with model lipid membranes. FEBS Lett. (2002) 532(1-2): 115-120.
33. BOWDISH DME, HANCOCK REW: And-endotoxin properties of cationic host defence peptides and proteins. J. Endotox. Res. (2005) 11:230-236.
34. SORENSEN OE, FOLLIN P, JOHNSEN AH et al.: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood (2001) 97( 12):3951-3959.
35. GANZ T: Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. (2003) 3(9):710-720.
36. SELSTED ME, OUELLETTE AJ: Mammalian defensins in the antimicrobial immune response. Nat. Immunol. (2005) 6(6):551-557.
37. DIAMOND G, RUSSELL JP, BEVINS CL: Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc. Natl. Acad. Sci. USA (1996) 93:5156-5160.
38. HARDER J, MEYER-HOFFERT U, WEHKAMP K, SCHWICHTENBERG L, SCHRODER JM: Differential gene induction of human β-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J. Invest. Dermatol. (2004) 123(3):522-529.
39. PROUD D, SANDERS SP, WIEHLER S: Human rhinovirus infection induces airway epithelial cell production of human β-defensin 2 both in vitro and in vivo. J. Immunol. (2004) 172(7):4637-4645.
40. YANG D, CHEN Q, CHERTOV O, OPPENHEIM JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. (2000) 68(1):9-14.
41. BALS R, WEINER DJ, MOSCIONI AD, MEEGALLA RL, WILSON JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immunol. (1999) 67(11):6084-6089.
42. NIZET V, OHTAKE T, LAUTH X et al.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (2001) 414(6862):454-457.
43. PUTSEP K, CARLSSON G, BOMAN HG, ANDERSSON M: Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet (2002) 360(9340):1144-1149.
44. ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. (2002) 347(15):1151-1160.
45. WANG Z, WANG G: APD: the antimicrobial peptide database. Nucl. Acids Res. (2004) 32(Suppl. 1):D590-D592.
46. BRAHMACHARY M, KRISHNAN SPT, KOH JLY et al.: ANTIMIC: a database of antimicrobial sequences. Nucl. Acids. Res. (2004) 32(Suppl. 1):D586-D589.
47. SEEBAH S, SURESH A, ZHUO S et al.: Defensins knowledgebase: a manually curated database and information source focused on the defensins family of antimicrobial peptides. Nucl. Acids Res. (2007) 35(Suppl. 1):D265-D268.
48. HANCOCK REW, PATRZYKAT A: Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug Targets Infect. Disord. (2002) 2(1):79-83.
49. HILPERT K, VOLKMER-ENGERT R, WALTER T, HANCOCK REW: High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. (2005) 23(8):1008-1012.
50. HILPERT K, ELLIOTT MR, VOLKMER-ENGERT R et al.: Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem. Biol. (2006) 13(10):1101-1107.
51. CIRIONI O, GIACOMETTI A, GHISELLI R et al.: LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. (2006) 50(5):1672-1679.
52. GIACOMETTI A, CIRIONI O, GHISELLI R et al.: The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit. Care Med. (2004) 32(12):2485-2490.
53. GIACOMETTI A, CIRIONI O, GHISELLI R et al.: Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am. J. Respir. Crit. Care Med. (2004) 169(2):187-194.
54. BOWDISH DM, DAVIDSON DJ, LAU YE et al.: Impact of LL-37 on and-infective immunity. J. Leukoc. Biol. (2005) 77(4):451-459.
55. SCOTT MG, DAVIDSON DJ, GOLD MR, BOWDISH D, HANCOCK REW: The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. (2002) 169(7):3883-3891.
56. BOWDISH DM, HANCOCK REW: Anti-endotoxin properties of cationic host defence peptides and proteins. J. Endotox. Res. (2005) 11(4):230-236.
57. MOOKHERJEE N, WILSON HL, DORIA S et al.: Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. J. Leukoc. Biol. (2006) 80(6):1563-1574.
58. BOSSHART H, HEINZELMANN M: Human neutrophil-derived CAP37 inhibits lipopolysaccharide-induced activation in murine peritoneal macrophages. Immunol. Lett. (2004) 94(3):175-182.
59. HANCOCK REW: Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. (2001) 1(3):156-164.
60. ZHANG L, SCOTT MG, YAN H, MAYER LD, HANCOCK REW: Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry (2000) 39(47): 14504-14514.
61. NIZET V, GALLO RL: Cathelicidins and innate defense against invasive bacterial infection. Scand. J. Inject. Dis. (2003) 35(9):670-676.
62. GOUGH M, HANCOCK REW, KELLY NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immunol. (1996) 64(12):4922-4927.
63. ROSENFELD Y, PAPO N, SHAI Y: Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem. (2006) 281(3):1636-1643.
64. TJABRINGA GS, AARBIOU J, NINABER DK et al.: The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. (2003) 171(12):6690-6696.
65. SCOTT MG, VREUGDENHIL AC, BUURMAN WA, HANCOCK REW, GOLD MR: Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J. Immunol. (2000) 164(2):549-553.
66. SCOTT MG, ROSENBERGER CM, GOLD MR, FINLAY BB, HANCOCK REW: An α-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J. Immunol. (2000) 165(6):3358-3365.
67. FINLAY BB, HANCOCK REW: Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. (2004) 2(6):497-504.
68. NIYONSABA F, IWABUCHI K, MATSUDA H, OGAWA H, NAGAOKA I: Epithelial cell-derived human α-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int. Immunol. (2002) 14(4):421-426.
69. TERRITO M, GANZ T, SELSTED M, LEHPER R: Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. (1989) 84(6):2017-2020.
70. DE Y, CHEN Q, SCHMIDT AP et al.: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. (2000) 192(7):1069-1074.
71. BALS R, WILSON JM: Cathelicidins - a family of multifunctional antimicrobial peptides. Cell Mol. Life Sci. (2003) 60(4):711-720.
72. TJABRINGA GS, NINABER DK, DRIJFHOUT JW, RABE KF, HIEMSTRA PS: Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol. (2006) 140(2):103-112.
73. DAVIDSON DJ, CURRIE AJ, REID GS et al.: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarizadon. J. Immunol. (2004) 172(2):1146-1156.
74. BOWDISH DM, DAVIDSON DJ, SPEERT DP, HANCOCK REW: The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. (2004) 172(6):3758-3765.
75. CHEN X, NIYONSABA F, USHIO H et al: Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J. Dermatol. Sci. (2006) 43(1):63-66.
76. TOKUMARU S, SAYAMA K, SHIRAKATA Y et al.: Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. (2005) 175(7):4662-4668.
77. NIYONSABA F, IWABUCHI K, MATSUDA H, OGAWA H, NAGAOKA I: Epithelial cell-derived human β-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int. Immunol. (2002) 14(4):421426.
78. TERRITO MC, GANZT, SELSTED ME, LEHRER R: Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. (1989) 84(6):2017-2020.
79. SAIDO-SAKANAKA H, ISHIBASHI J, MOMOTANI E, AMANO F, YAMAKAWA M: In vitro and in vivo activity of antimicrobial peptides synthesized based on the insect defensin. Peptides (2004) 25(1):19-27.
80. MOTOBU M, AMER S, YAMADA M et al.: Effects of antimicrobial peptides derived from the beetle Allomyrina dichotoma defensin on mouse peritoneal macrophages stimulated with lipopolysaccharide. J. Vet. Med. Sci. (2004) 66(3):319-322.
81. KOYAMA Y, MOTOBU M, HIKOSAKA K et al.: Protective effects of antimicrobial peptides derived from the beetle Allomyrina dichotoma defensin on endotoxic shock in mice. Int. Immunopharmacol. (2006) 6(2):234-240.
82. MOTZKUS D, SCHULZ-MARONDE S, HEITLAND A et al.: The novel β-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J. (2006) 20(10):1701-1702.
83. SALZMAN NH, GHOSH D, HUTTNER KM, PATERSON Y, BEVINS CL: Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 422(6931):522-526.
84. SHU Q, SHI Z, ZHAO Z et al.: Protection against Pseudomonas aeruginosa pneumonia and sepsis-induced lung injury by overexpression of β-defensin-2 in rats. Shock (2006) 26(4):365-371.
85. LEVY MM, FINK MP, MARSHALL JC et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. (2003) 31(4):1250-1256.
86. BARSKY A, GARDY JL, HANCOCK REW, MUNZNER T: Cerebral: a cytoscape plugin for layout of and interaction with biological networks using subcellular localization annotation. Bioinformatics (2007) 23(8):1040-1042.
87. SCOTT MG, DULLAGHAN E, MOOKHERJEE N et al.: An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. (2007) 25(4):465-472.
88. SAWAT, KURAHASHI K, OHARA M et al.: Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob. Agents Chemother. (1998) 42(12):3269-3275.
89. SIGURDARDOTTIR T, ANDERSSON P, DAVOUDI M et al.: In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrob. Agents Chemother. (2006) 50(9):2983-2989.
90. NAGAOKA I, TAMURA H, HIRATA M: An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J. Immunol. (2006) 176(5):3044-3052.
91. HANCOCK REW, SAHL HG: Antimicrobial and host-defense peptides as new and-infective therapeutic strategies. Nat. Biotechnol. (2006) 24(12):1551-1557.
92. CIRIONI O, GIACOMETTI A, GHISELLI R et al.: Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides (2006) 27(9):2104-2110.
93. VOGEL SN, FITZGERALD KA, FENTON MJ: TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. (2003) 3(8):466-477.
94. MIGGIN SM, O'NEILL LA: New insights into the regulation of TLR signaling. J. Leukoc. Biol. (2006) 80(2):220-226.
95. FITZGERALD KA, CHEN ZJ: Sorting out Toll signals. Cell (2006) 125(5):834-836.
96. MOOKHERJEE N, HANCOCK REW: Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. (2007) 64(7-8):922-933.
97. BOWDISH DM, DAVIDSON DJ, HANCOCK REW: A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Prot. Pept. Sci. (2005) 6(1):35-51.